Fierce Pharma

JANUARY 5, 2024

Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medi | Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medical records of patients shows no link between use of the GLP-1 drugs and an increase in suicidal though

Side effects 293

Side effects Medicine FDA Medical 293

MedCity News

JANUARY 5, 2024

A bipartisan group of senators sent a letter to HHS asking it to rethink its appeal of a recent federal district court decision that limits the use of “copay accumulators” — which are programs insurers use to prevent medication copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.

Insurance 125

Insurance Medical Patients Pharma 125

Fierce Pharma

JANUARY 5, 2024

When Theravance called it quits on a phase 2 JAK inhibitor program last February, the South San Francisco and Dublin-based biopharma company put the majority of its chips on a head-to-head trial pi | In the phase 4 study, Theravance and Viatris’ Yupelri failed to demonstrate greater lung function improvement in adults with COPD versus Spiriva delivered by a dry powder inhaler, Theravance said Friday.

Biopharma 202

Biopharma 202

MedCity News

JANUARY 5, 2024

Check out news from Kismet Health, the University of California at Berkeley’s life science startups, and the companies presenting at the Consumer Technology Association’s pitch contest at CES.

Healthcare 118

Healthcare Healthcare 118

Advertisement

Distribution

Fierce Pharma

JANUARY 5, 2024

The last few days of 2023 and the beginning of 2024 featured a flurry of dealmaking by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies | A flurry of deals were inked by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies. Big Pharma companies are also increasingly entrusting commercialization of some products in China to domestic firms.

Pharma 179

Pharma 179

MedCity News

JANUARY 5, 2024

Crowded EDs will continue to plague the healthcare ecosystem and prevent the efficient delivery of care if the structure and education of care, resources, and availability are kept the same. UC can step in with its well-equipped and trained staff so that EDs can focus on what they do best, care for life-threatening situations.

Education 107

Education Training Healthcare Healthcare 107

Pharmaceutical Commerce

JANUARY 5, 2024

LillyDirect will facilitate access to medications by connecting patients with independent telehealth providers, bypassing the need to obtain a prescription from a physician and then going to a pharmacy to fill it.

Prescription 105

Prescription Physicians Medical Patients 105

European Pharmaceutical Review

JANUARY 5, 2024

Under a new licensing agreement, Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, gains the global rights to develop and commercialise a novel, small molecule KAT6A inhibitor. This treatment has potential for hormone sensitive cancers such as breast cancer, and other oncology indications. The therapeutic is designed using the artificial intelligence (AI)-platform from Insilico Medicine, the biotech company that is also part of this collaboration.

Medicine 105

Medicine Biopharma Patients Pharmaceutical 105

MedCity News

JANUARY 5, 2024

In predicting that the Medi-Cal coverage protections during the pandemic would end, advocates successfully pushed for California to adopt a continuous Medi-Cal coverage policy for children ages 0-5 – avoiding annual renewals during this vulnerable time in their childhood development. For this important protection to become a reality as soon as possible, we now need the Governor to fund and greenlight this policy immediately–in his January 2024 Budget proposal.

100

100

Pharmaceutical Technology

JANUARY 5, 2024

AbbVie and Umoja Biopharma partnered for the development of in-situ CAR-T cell therapy candidates for oncology targets.

Biopharma 122

Biopharma 122

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

JANUARY 5, 2024

Solera Health has added virtual specialty care services to its Halo Platform. The new offering is in partnership with 9amHealth, Vori Health and Oshi Health.

104

104

PharmaVoice

JANUARY 5, 2024

Although three companies dominate the space, emerging infectious disease focus areas and a handful of other key players are augmenting the market.

Marketing 105

Marketing 105

MedCity News

JANUARY 5, 2024

As we look into the future, 2024 promises a profound transformation. Here are five areas of focus for the upcoming year.

Healthcare 113

Healthcare Healthcare 113

Healthcare Success

JANUARY 5, 2024

Managing a PPC strategy for any sized business is complex and challenging. But organizations with dozens or hundreds of locations face even more hurdles: Multilocation providers must consider each location’s unique needs, competitive situation, and business objectives—compounding the complexity of managing an accurate and effective PPC (aka pay-per-click or paid search) strategy.

Healthcare 72

Healthcare Healthcare Management Marketing 72

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

pharmaphorum

JANUARY 5, 2024

Beckley Psytech has announced that is has received substantial strategic investment from atai Life Sciences, totalling $50 million, to accelerate the clinical development of short-duration psychedelics.

70

70

PharmExec

JANUARY 5, 2024

The LillyDirect platform will allow patients who are prescribed the popular weight loss drug Zepbound to obtain the drug via Lilly’s at-home prescription delivery service.

Prescription 96

Prescription Patients 96

PharmaTimes

JANUARY 5, 2024

The companies will aim to select targets, discover and develop new therapeutics

90

90

Clarify Health

JANUARY 5, 2024

Welcome to our new podcast, Healthcare Unbound , where healthcare leaders and changemakers discuss ways to advance healthcare outcomes, costs, and affordability. Healthcare Unbound offers listeners a front-row seat to some of the brightest minds working to find solutions to the immense challenges we are facing in every corner of the industry. The podcast is the namesake of the Healthcare Unbound Summit we held in May 2022, where a select group of 150 industry thought leaders, innovators, and

Healthcare 52

Healthcare Healthcare Physicians Healthcare Provider 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmaTimes

JANUARY 5, 2024

Vd1-gd T cells were effective in predicting positive responses to ICI therapy

Patients 91

Patients 91

Pharmaceutical Commerce

JANUARY 5, 2024

Trials will evaluate four novel agents for cancers that include essential thrombocythemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-small cell lung cancer, endometrial carcinoma, and metastatic castration-resistant prostate cancer.

52

52

PM360

JANUARY 5, 2024

Novo Nordisk, Omega Therapeutics, Inc. and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.

Medicine 52

Medicine Management Patients Sales 52

PharmExec

JANUARY 5, 2024

Tina Fresta, BA, MPH is the Strategic Solutions Senior Manager at epocrates, keeps a close eye on the pharmaceutical and bio science industry shifts, leveraging those insights to inform both our partners and our company of the most strategic approach to reach business goals.

Management 52

Management Pharmaceutical 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

Pharmaceutical Technology

JANUARY 5, 2024

Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.

64

64

Pharmaceutical Commerce

JANUARY 5, 2024

In the midst of being approved for commercial manufacturing of Pluvict, the 70,000 square-foot site was built specifically to accommodate RLT production.

Manufacturing 52

Manufacturing 52

Pharmaceutical Technology

JANUARY 5, 2024

A BBC team was able to buy over 1600 prescription pills by supplying fake data, raising concerns over limited oversight.

Prescription 59

Prescription Media 59

PharmExec

JANUARY 5, 2024

Trial data show 89Zr-DFO-girentuximab was more effective than traditional PET/CT imaging in identifying malignant renal cell carcinoma lesions.

Pharmaceutical 52

Pharmaceutical 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PharmaTech

JANUARY 5, 2024

MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.

52

52

Pharmaceutical Technology

JANUARY 5, 2024

KAI, a technology company based in the UK, is a Category Award Winner for Innovation in the 2023 Pharmaceutical Technology Excellence Awards

Pharmaceutical 52

Pharmaceutical 52

PharmExec

JANUARY 5, 2024

Merck is actively enrolling patients across Phase III trials for four novel candidates for hematologic malignancies and solid tumors.

Patients 52

Patients 52

Pharmaceutical Technology

JANUARY 5, 2024

Avistone has closed its Series B financing round, raising 1bn yuan ($140m), to support clinical research and development of its drug pipeline.

52

52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management